Generic placeholder image

Current Protein & Peptide Science

Author(s): Luciano Benedini*

DOI: 10.2174/1389203722666211210115040

DownloadDownload PDF Flyer Cite As
Advanced Protein Drugs and Formulations

Page: [2 - 5] Pages: 4

  • * (Excluding Mailing and Handling)

Abstract

Previously, the application of proteins was uncommon as therapeutically active molecules. Some of the first applications of proteins as drugs have been insulin and vaccines for overcoming a physiological deficiency and the prevention of diseases, respectively. Nowadays, proteins have many applications, not only as drugs but also as drug delivery systems to be administered by different routes. Due to their nature, the behavior of proteins varies while the conditions of the environment are modified. For this reason, it is necessary to study their behavior for predicting the correct manufacturing, storing, or combination with other possible molecules in a formulation or into the body. The application of techniques for predicting the behavior of proteins in different environments has led to associating this type of behavior into the body with the occurrence of diseases, such as celiac disease or Alzheimer's disease. Thus, this work shows an overview of the main types of proteins applied as active therapeutically molecules, proteins-based drug delivery systems, and techniques for predicting their stability into the primary storing container and the body.

Graphical Abstract

[1]
Leader, B.; Baca, Q.J.; Golan, D.E. Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov., 2008, 7(1), 21-39.
[http://dx.doi.org/10.1038/nrd2399] [PMID: 18097458]
[2]
Lee, A.C-L.; Harris, J.L.; Khanna, K.K.; Hong, J-H. A comprehensive review on current advances in peptide drug development and design. Int. J. Mol. Sci., 2019, 20(10), 2383.
[http://dx.doi.org/10.3390/ijms20102383] [PMID: 31091705]
[3]
Reichert, J.M. Trends in development and approval times for new therapeutics in the United States. Nat. Rev. Drug Discov., 2003, 2(9), 695-702.
[http://dx.doi.org/10.1038/nrd1178] [PMID: 12951576]
[4]
Reily, C.; Stewart, T.J.; Renfrow, M.B.; Novak, J. Glycosylation in health and disease. Nat. Rev. Nephrol., 2019, 15(6), 346-366.
[http://dx.doi.org/10.1038/s41581-019-0129-4] [PMID: 30858582]
[5]
Balasubramanian, V.; Onaca, O.; Enea, R.; Hughes, D.W.; Palivan, C.G. Protein delivery: from conventional drug delivery carriers to polymeric nanoreactors. Expert Opin. Drug Deliv., 2010, 7(1), 63-78.
[http://dx.doi.org/10.1517/17425240903394520] [PMID: 19961359]
[6]
Tang, L.; Persky, A.M.; Hochhaus, G.; Meibohm, B. Pharmacokinetic aspects of biotechnology products. J. Pharm. Sci., 2004, 93(9), 2184-2204.
[http://dx.doi.org/10.1002/jps.20125] [PMID: 15295780]
[7]
Dimitrov, D.S. Therapeutic Proteins. Methods Mol. Biol., 2012, 1-26.
[http://dx.doi.org/10.1007/978-1-61779-921-1_1]
[8]
Pouwer, F.; Hermanns, N. Insulin therapy and quality of life. A review. Diabetes Metab. Res. Rev., 2009, 25(Suppl. 1), S4-S10.
[http://dx.doi.org/10.1002/dmrr.981] [PMID: 19662621]
[9]
Miles, S. The use of hematopoietic growth factors in treating HIV infection. Curr. Opin. Hematol., 1995, 2(3), 227-233.
[http://dx.doi.org/10.1097/00062752-199502030-00012] [PMID: 9372000]
[10]
Steensma, D.P. Hematopoietic growth factors in myelodysplastic syndromes. Semin. Oncol., 2011, 38(5), 635-647.
[http://dx.doi.org/10.1053/j.seminoncol.2011.04.014] [PMID: 21943670]
[11]
Polzien, F.; Schott, P.; Mihm, S.; Ramadori, G.; Hartmann, H. Interferon-α treatment of hepatitis C virus-associated mixed cryoglobulinemia. J. Hepatol., 1997, 27(1), 63-71.
[http://dx.doi.org/10.1016/S0168-8278(97)80281-4] [PMID: 9252075]
[12]
Steinberg, S.C.; Faris, R.J.; Chang, C.F.; Chan, A.; Tankersley, M.A. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin. Drug Investig., 2010, 30(2), 89-100.
[http://dx.doi.org/10.2165/11533330-000000000-00000] [PMID: 20067327]
[13]
Blick, S.K.A.; Scott, L.J. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs, 2007, 67(17), 2585-2607.
[http://dx.doi.org/10.2165/00003495-200767170-00008] [PMID: 18034592]
[14]
Heath, P.T.; Galiza, E.P.; Baxter, D.N.; Boffito, M.; Browne, D.; Burns, F. Jun 30; Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med., 2021. , NEJMoa2107659.
[15]
Richmond, P.; Hatchuel, L.; Dong, M.; Ma, B.; Hu, B.; Smolenov, I.; Li, P.; Liang, P.; Han, H.H.; Liang, J.; Clemens, R. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet, 2021, 397(10275), 682-694.
[http://dx.doi.org/10.1016/S0140-6736(21)00241-5] [PMID: 33524311]
[16]
Bhawani, S.A.; Husaini, A.; Ahmad, F.B.; Asaruddin, M.R. Polymer based protein therapeutics. Curr. Protein Pept. Sci., 2018, 19(10), 972-982.
[http://dx.doi.org/10.2174/1389203718666170821162823] [PMID: 28828988]
[17]
Benedini, L.A.; Messina, P.V. Nanodevices for facing new challenges of medical treatments: stimuli-responsive drug delivery systems. Syst Rev Pharm., 2021, 12(2), 43-64.
[18]
Sartuqui, J.; D'Elía, N.; Noel, A.; Benedini, L. Application of natural, semi-synthetic, and synthetic biopolymers used in drug delivery systems design. Biopol. Med. Appl., 2016, 38-65.
[19]
Messina, P.V.; Benedini, L.A.; Placente, D. Nanotechnology application in tissue regeneration and regenerative medicine: smart tools in modern healthcare. In: tomorrow's healthcare by nano-sized approaches; CRC Press, CRC Press: Boca Raton; , 2020; pp. 235-75.
[20]
Quirolo, Z.B.; Benedini, L.A.; Sequeira, M.A.; Herrera, M.G.; Veuthey, T.V.; Dodero, V.I. Understanding recognition and self-assembly in biology using the chemist’s toolbox. Insight into medicinal chemistry. Curr. Top. Med. Chem., 2014, 14(6), 730-739.
[http://dx.doi.org/10.2174/1568026614666140118220825] [PMID: 24444155]
[21]
Messina, P.V. Tomorrow’s Healthcare by Nano-sized Approaches. CRC Press Taylor and Francis; CRC Press: Boca Raton, 2020, p. 292.
[http://dx.doi.org/10.1201/9780429400360]
[22]
Sartuqui, J.; Gravina, A.N.; Rial, R.; Benedini, L.A.; Yahia, L.; Ruso, J.M.; Messina, P.V. Biomimetic fiber mesh scaffolds based on gelatin and hydroxyapatite nano-rods: Designing intrinsic skills to attain bone reparation abilities. Colloids Surf. B Biointerfaces, 2016, 145, 382-391.
[http://dx.doi.org/10.1016/j.colsurfb.2016.05.019] [PMID: 27220014]
[23]
Aguzzi, A.; O’Connor, T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat. Rev. Drug Discov., 2010, 9(3), 237-248.
[http://dx.doi.org/10.1038/nrd3050] [PMID: 20190788]
[24]
Benedini, L.A.; Vidal, N.L.G.; Gonzalez, M.A. Celiac disease: historical standpoint, new perspectives of treatments and contemporary research techniques. Curr. Protein Pept. Sci., 2018, 19(11), 1058-1070.
[http://dx.doi.org/10.2174/1389203719666180531123514] [PMID: 29852868]
[25]
Llamas-Saiz, A.L.; van Raaij, M.J. X-Ray Crystallography of Biological Macromolecules: Fundamentals and Applications. In: proteins in solution and at interfaces; John Wiley & Sons, Inc.: Hoboken, NJ, USA ; , 2013; pp. 1-22.
[http://dx.doi.org/10.1002/9781118523063.ch1]
[26]
Maveyraud, L.; Mourey, L. Protein X-ray crystallography and drug discovery. Molecules, 2020, 25(5), 1030.
[http://dx.doi.org/10.3390/molecules25051030] [PMID: 32106588]
[27]
Wang, W. Advanced protein formulations. Protein Sci., 2015, 24(7), 1031-1039.
[http://dx.doi.org/10.1002/pro.2684] [PMID: 25858529]
[28]
van Dun, S.; Ottmann, C.; Milroy, L-G.; Brunsveld, L. Supramolecular chemistry targeting proteins. J. Am. Chem. Soc., 2017, 139(40), 13960-13968.
[http://dx.doi.org/10.1021/jacs.7b01979] [PMID: 28926241]
[29]
Shim, H. Bispecific antibodies and antibody-drug conjugates for cancer therapy: technological considerations. Biomolecules, 2020, 10(3), 360.
[http://dx.doi.org/10.3390/biom10030360] [PMID: 32111076]